Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme

NCT00323115 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma Multiforme

Interventions

BIOLOGICAL: Autologous Dendritic Cell
DRUG: Temozolomide
PROCEDURE: Radiotherapy
BIOLOGICAL: Dendritic Cell Vaccine

Sponsor

Dartmouth-Hitchcock Medical Center